6/18
11:07 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
5/31
08:03 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
5/30
07:24 am
roiv
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update [Yahoo! Finance]
Medium
Report
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update [Yahoo! Finance]
5/30
07:00 am
roiv
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
Medium
Report
Roivant Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provides Business Update
5/27
12:44 pm
roiv
Vivek Ramaswamy Offers His Take on How So Many Politicians Become Millionaires [Yahoo! Finance]
Low
Report
Vivek Ramaswamy Offers His Take on How So Many Politicians Become Millionaires [Yahoo! Finance]
5/22
05:04 pm
roiv
Vivek Ramaswamy, Far-Right Politician And Investor, Buys 7.7% Stake In BuzzFeed [Yahoo! Finance]
Medium
Report
Vivek Ramaswamy, Far-Right Politician And Investor, Buys 7.7% Stake In BuzzFeed [Yahoo! Finance]
5/22
10:08 am
roiv
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? [Yahoo! Finance]
Low
Report
Vivek Ramaswamy Breathes New Life Into Beaten Down BuzzFeed Stock: What's Going On? [Yahoo! Finance]
5/22
09:14 am
roiv
Former Republican Presidential Hopeful Vivek Ramaswamy Acquires Activist Stake in BuzzFeed [Yahoo! Finance]
Low
Report
Former Republican Presidential Hopeful Vivek Ramaswamy Acquires Activist Stake in BuzzFeed [Yahoo! Finance]
5/22
08:35 am
roiv
BuzzFeed Shares Soar as Vivek Ramaswamy Takes Stake, Seeks Talks [BNN Bloomberg (Canada)]
Low
Report
BuzzFeed Shares Soar as Vivek Ramaswamy Takes Stake, Seeks Talks [BNN Bloomberg (Canada)]
5/21
08:11 am
roiv
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD [Yahoo! Finance]
Low
Report
Dermavant Announces Publication of ADORING 1 & ADORING 2 Pivotal Phase 3 Trials of VTAMA® (tapinarof) cream, 1% for Adults and Children 2 Years of Age and Older with Atopic Dermatitis in JAAD [Yahoo! Finance]
5/20
09:58 am
roiv
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
Low
Report
Compugen (CGEN) Reports Q1 Loss, Misses Revenue Estimates [Yahoo! Finance]
5/16
04:05 pm
roiv
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
Low
Report
Roivant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2024, and Provide Business Update on Thursday, May 30, 2024
5/5
09:03 am
roiv
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain [Yahoo! Finance]
Low
Report
Institutional investors are Roivant Sciences Ltd.'s (NASDAQ:ROIV) biggest bettors and were rewarded after last week's US$290m market cap gain [Yahoo! Finance]
4/29
08:10 am
roiv
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]
Low
Report
Dermavant Announces FDA Acceptance of Supplemental New Drug Application (sNDA) for VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older [Yahoo! Finance]
4/25
08:00 am
roiv
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
Low
Report
Roivant and Kinevant Sciences Complete Enrollment in RESOLVE-Lung, a Phase 2 Study Evaluating Namilumab for Chronic Pulmonary Sarcoidosis
4/24
03:46 pm
roiv
Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]
Low
Report
Roivant Sciences: Cashing In On Vants And Ventures [Seeking Alpha]
4/22
08:13 am
roiv
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]
Low
Report
OSR Holdings and SillaJen have entered into a Memorandum of Understanding to collaboratively pursue the development of innovative therapeutics and enter the U.S. market [Yahoo! Finance]
4/22
08:09 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
Low
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $18.00 price target on the stock.
4/3
12:29 pm
roiv
Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]
Medium
Report
Arbutus Biopharma jumps after patent victory in fight with Moderna [Seeking Alpha]
4/3
12:12 pm
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $16.00 to $18.00. They now have a "buy" rating on the stock.
4/3
08:08 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $15.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $14.00 to $15.00. They now have a "buy" rating on the stock.
4/3
08:08 am
roiv
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
Medium
Report
Roivant Sciences Ltd. (NASDAQ: ROIV) had its price target raised by analysts at HC Wainwright from $17.00 to $18.00. They now have a "buy" rating on the stock.
4/2
02:48 pm
roiv
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study [Yahoo! Finance]
Low
Report
Vivek Ramaswamy-Founded Roivant's Anti-Inflammatory Drug Aces Mid-Stage Study [Yahoo! Finance]
4/2
07:05 am
roiv
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million [Yahoo! Finance]
Low
Report
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million [Yahoo! Finance]
4/2
07:00 am
roiv
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Low
Report
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million